推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Cancer Communications

2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 CANCER COMMUN最新评论:是的 大修 (2024-03-20)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


Cancer Communications期刊基本信息Hello,您是该期刊的第51220位访客

基本信息 登录收藏
期刊名字Cancer CommunicationsCancer Communications

CANCER COMMUN
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
6.9
51人评分
我要评分

声誉
8.1

影响力
6.0

速度
7.0

期刊ISSN2523-3548
微信扫码收藏此期刊
2022-2023最新影响因子
(数据来源于搜索引擎)
16.2 点击查看影响因子趋势图
实时影响因子 截止2024年3月26日:18.917
2022-2023自引率4.30%点击查看自引率趋势图
五年影响因子14.4
h-index 暂无h-index数据
CiteScore
CiteScoreSJRSNIPCiteScore排名
19.902.6773.054
学科分区排名百分位
大类:Medicine
小类:Oncology
Q120 / 366
大类:Medicine
小类:Cancer Research
Q115 / 214

期刊简介
Cancer Communications is an open access, peer-reviewed online journal that aims to publish significant advances across the full specturm of cancer research spanning basic, clinical, and translational work. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics. Article types include Original Article,Review, Commentary, Research Highlight, Letter to the Editor, News and Views, Guideline and Consensus, Short Report, Study protocol, Correspondence and Editorial.

Cancer Communications是一本开放获取、同行评议的在线期刊,旨在发表关于跨越基础、临床和转化工作的全领域癌症研究重大进展情况的文章。该期刊欢迎有关临床试验、流行病学、分子和细胞生物学以及遗传学的稿件。文章类型包括原创文章、综述、评论、研究重点、新闻和观点、指南、简短报告、研究方案、通信和社论。
期刊官方网站https://onlinelibrary.wiley.com/journal/25233548
期刊投稿网址https://mc.manuscriptcentral.com/cac2
期刊语言要求Language
Manuscripts must be written in American English and be grammatically and linguistically correct. Authors should seek assistance with style, grammar and vocabulary if necessary. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Cancer Communications的语言要求,还能让Cancer Communications编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Cancer Communications编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问Yes
OA期刊相关信息
文章处理费:需要( USD2800; GBP2100; EUR2400; )
文章处理费豁免:查看说明

其他费用:没有
期刊主题关键词:clinical trials、epidemiology、cellular biology、cancer、molecular biology、genetics
相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
通讯方式111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774
出版商Wiley
涉及的研究方向Biochemistry, Genetics and Molecular Biology-Cancer Research
出版国家或地区PEOPLES R CHINA
出版语言English
出版周期Monthly
出版年份2018
年文章数 62点击查看年文章数趋势图
Gold OA文章占比58.86%
研究类文章占比:
文章 ÷(文章 + 综述)
64.52%
WOS期刊SCI分区
2022-2023年最新版
WOS分区等级:1区

按学科分区JIF分区JIF排名JIF百分位
学科:ONCOLOGY
类别:SCIE
Q115/241
中科院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中科院SCI期刊分区
2023年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区1区1区
ONCOLOGY
肿瘤学
4区4区2区
中科院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区1区2区
ONCOLOGY
肿瘤学
2区3区1区
中科院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 4区1区2区
ONCOLOGY
肿瘤学
1区1区1区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2523-3548%5BISSN%5D
平均审稿速度网友分享经验:
4 Weeks
平均录用比例网友分享经验:
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在Cancer Communications顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 Cancer Communications期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 Cancer Communications中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
Cancer Communications上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CELLULAR ONCOLOGY010.40
    Translational Oncology417.20
    Frontiers in Oncology605.20
    Journal of Gastric Cancer225.20
    Molecular and Cellular Oncology03.00
    Clinical and Experimental Morphology00.40
    Critical Reviews in Oncogenesis02.50
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE607014
    BIOMATERIALS517734
    BIOMEDICINE & PHARMACOTHERAPY470063
    Journal of Materials Chemistry B463018
    Frontiers in Pharmacology454769
    Frontiers in Immunology426441
    JOURNAL OF ETHNOPHARMACOLOGY409722
    COLLOIDS AND SURFACES B-BIOINTERFACES406606
    Frontiers in Oncology387670
    Acta Biomaterialia379253
  •  

    Cancer Communications Cancer Communications
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

    Author: Yang, Hang; Zhou, Xinyi; Fu, Dongliang; Le, Chenqin; Wang, Jiafeng; Zhou, Quan; Liu, Xiangrui; Yuan, Ying; Ding, Kefeng; Xiao, Qian
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 42-74. DOI: 10.1002/cac2.12377
        PubMed      DOI
    2.circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer

    Author: Yang, Yufei; Luo, Dakui; Shao, Yang; Shan, Zezhi; Liu, Qi; Weng, Junyong; He, Weijing; Zhang, Ruoxin; Li, Qingguo; Wang, Ziliang; Li, Xinxiang
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 100-122. DOI: 10.1002/cac2.12380
        PubMed      DOI
    3.Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma

    Author: Zhan, Xi; Wu, Rui; Kong, Xue-Hua; You, Yan; He, Kun; Sun, Xiao-Yu; Huang, Yong; Chen, Wei-Xian; Duan, Liang
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 225-245. DOI: 10.1002/cac2.12388
        PubMed      DOI
    4.Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality

    Author: Zhang, Lu; Li, Qingya; Yang, Jing; Xu, Penghui; Xuan, Zhe; Xu, Jianghao; Xu, Zekuan
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 123-149. DOI: 10.1002/cac2.12386
        PubMed      DOI
    5.Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions

    Author: Chen, Yu-Fei; Xu, Ying-ying; Shao, Zhi-Ming; Yu, Ke-Da
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 3, pp. 297-337. DOI: 10.1002/cac2.12387
        PubMed      DOI
    6.Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?

    Author: Feng, Ruimei; Su, Qingling; Huang, Xiaoyin; Basnet, Til; Xu, Xin; Ye, Weimin
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 75-86. DOI: 10.1002/cac2.12393
        PubMed      DOI
    7.Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives

    Author: Fang, Zengli; Meng, Qingcai; Xu, Jin; Wang, Wei; Zhang, Bo; Liu, Jiang; Liang, Chen; Hua, Jie; Zhao, Yingjun; Yu, Xianjun; Shi, Si
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 3-41. DOI: 10.1002/cac2.12392
        PubMed      DOI
    8.Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors

    Author: Liu, Fei; Wang, Zixian; Li, Xiaofan; Zhang, Zhen; Yang, Yue; Chen, Junquan; Chen, Dinghua; Wu, Lingling; Liu, Xiangyu; Han, Sujun; Wang, Fangming; Wahafu, Wasilijiang; Gao, Yibo; Ren, Shancheng; Xing, Nianzeng; Cai, Guangyan; Chen, Xiangmei
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 214-224. DOI: 10.1002/cac2.12396
        PubMed      DOI
    9.Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin

    Author: Zhao, Yuanyuan; Zhao, Bing; Chen, Gang; Chen, Yinlan; Liao, Zijun; Zhang, Haiming; Feng, Weineng; Li, Yinyin; Weng, Heng; Li, Weidong; Zhou, Yuefen; Ren, Biyong; Lu, Yanda; Chen, Jianhua; Liu, Zhenteng; Su, Zhenzhong; Wang, Wenliang; Zhang, Li
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 246-256. DOI: 10.1002/cac2.12397
        PubMed      DOI
    10.Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial

    Author: Lin, Qing; Zheng, Shangyou; Yu, Xianjun; Chen, Meifu; Zhou, Yu; Zhou, Quanbo; Hu, Chonghui; Gu, Jing; Xu, Zhongdong; Wang, Lin; Liu, Yimin; Liu, Qingyu; Wang, Min; Li, Guolin; Cheng, He; Zhou, Dongkai; Liu, Guodong; Fu, Zhiqiang; Long, Yu; Li, Yixiong; Wang, Weilin; Qin, Renyi; Li, Zhihua; Chen, Rufu
    Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 257-275. DOI: 10.1002/cac2.12399
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386164.40
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE REVIEWS MICROBIOLOGY25060.20


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共147条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451